Home
overview
The use of oligonucleotides as therapeutic agents rests upon their ability to interfere, in a sequence-specific manner, with the fundamental machinery of protein synthesis either by binding to the mRNAs transcribed from a gene or by binding directly to a target gene. This approach can be used not only for inhibition of the synthesis of host proteins but also of those required by invading pathogens.

Potential therapeutic applications are enormous, ranging over hypertension, cardiovascular disease, autoimmune disease, and viral infections especially HIV, and cancer. This meeting aims to bring together experts from within antisense research, to offer an insight into the novel therapeutic uses possible and the applications now available and future developments.

A unique opportunity to learn from leading industry experts including:
Dr Robert Klem, Vice President & Chief Technical Officer, Genta
Dr Frank Bennett, Vice President, Antisense Research, ISIS Pharmaceuticals
Dr Sudhir Agrawal, Chief Scientific Officer & President, Hybridon
Dr John Reidhaar-Olson, Head, Laboratory Genomics, Hoffmann-La Roche
Dr Vinod Subramaniam, Senior Research Scientist, Advanced Science & Technology Laboratory, AstraZeneca
Dr William John, Senior Clinical Research Physician, Eli Lilly
Dr Sumedha Jayasena, Research Scientist, Amgen

Benefits of attending:
Identify the key issues in antisense and SiRNA technologies
Learn how SiRNA is being successfully applied to target validation
Discover novel technologies in the antisense and SiRNA arena
Assess how functional genomics can work for you
Hear about recent antisense clinical trial results
Raise the profile of your company by learning from your leading competitors

“This cutting edge programme, covering both novel drug target validation strategies and recent results from clinical trials of antisense therapeutics, is a must for Biotech companies and big Pharma”
Dr Eugen Uhlmann, Vice President, Chemical Development, Coley Pharmaceutical

Conference programme

8:30 Registration and Coffee

9:00 Chairman's Opening Remarks

Dr Jutta Reinhard-Rupp

Dr Jutta Reinhard-Rupp, Head, Scientific Affairs, Germany, Aventis

9:10 KEYNOTE ADDRESS

Dr Frank Bennett

Dr Frank Bennett, Vice President, Antisense Research, ISIS Pharmaceuticals

  • There are multiple mechanisms of regulating gene expression with synthetic oligonucleotides
  • Each strategy has its own unique advantages and disadvantages
  • RNase H-dependent oligonucleotides are the most advanced
  • Multiple RNase H dependent oligonucleotides are in clinical trials, including several late stage products
  • Chemical modifications of oligonucleotides have broadened the utility of first generation drugs
  • Despite steady progress in the technology, far more questions than answers remain
  • 9:40 ANTISENSE THERAPEUTICS

    Dr Sudhir Agrawal

    Dr Sudhir Agrawal, Chief Scientific Officer & President, Hybridon

  • Inhibition of disease-associated proteins using antisense therapeutics
  • Developing advanced chemistry antisense agents
  • Development of antisense drugs as oral therapeutics
  • Antisense products in development for treatment of cancer: progress to date
  • Development of immunomodulatory oligonucleotides
  • 10:20 SiRNA

    Dr Nicola Parsons

    Dr Nicola Parsons, Technical Applications Specialist, Ambion

  • Current considerations for SiRNA design
  • SiRNA transfection
  • Successful silencing of target gene expression
  • Achieving stable expression of SiRNA in mammalian cells
  • Future developments
  • 11:00 Morning Coffee

    11:20 RNAI

    Dr Stefan Limmer

    Dr Stefan Limmer, Chief Scientific Officer, Ribopharma

  • Optimisation of SiRNAs with respect to in vivo applications
  • Adult GFP-transgenic mice as a model system for in vivo applications
  • Mouse xenograft models of tumour diseases (pancreat. carcin; malign. melanoma)
  • Other mouse disease models and virological applications
  • 12:00 eliRNA BASED MAMMALIAN GENE SILENCING

    Dr C Satishchandran

    Dr C Satishchandran, Chief Scientific Officer, Nucleonics

  • eliRNA technology
  • Therapeutic applications: attenuation of HIV and HBV
  • Applications in cancer, assigning gene function, identification and validation of therapeutic targets
  • Commercialisation of technology
  • 12:40 Lunch

    13:40 FUNCTIONAL GENOMICS

    Dr Tod Woolf

    Dr Tod Woolf, President, Sequitur

  • Gene function elucidation by RNA interference
  • Using predictive algorhythms for selection of antisense sequences
  • Preparation of oligonucleotides on automated equipment
  • Screening of antisense oligonucleotides using cell based assays
  • Working with scientists from therapeutic areas to validate new drug targets
  • Establishing links between novel genes and disease
  • 14:20 APTAMERS

    Charles Wilson

    Charles Wilson, Vice President, Technology, Archemix

  • Aptamer basics
  • Aptamer efficacy in disease models
  • Pharmacokinetic properties of aptamers as a class
  • Aptamers as protein knockout tools for drug discovery
  • 15:00 SiRNA: TARGET VALIDATION AND BEYOND

    Dr Sumedha Jayasena

    Dr Sumedha Jayasena, Research Scientist, Amgen

  • An approach for picking functional SiRNA triggers for gene targets
  • A brief comparison between antisense and RNAi technologies
  • Potency, specificity and duration of SiRNA mediated gene silencing
  • 15:40 Afternoon Tea

    16:00 TARGET VALIDATION

    Dr Nicholas Dean

    Dr Nicholas Dean, Vice President, Functional Genomics, Genetrove™, ISIS Pharmaceuticals

  • High-throughput gene functionalisation in vitro
  • Identification of novel pathway connections
  • Functional analysis of druggable target families (kinases)
  • Target validation in animal models of disease
  • 16:40 RNAI-BASED TARGET VALIDATION

    Dr John Reidhaar-Olson

    Dr John Reidhaar-Olson, Head, Laboratory Genomics, Hoffmann-La Roche

  • Integration of RNAi into a process biology approach to target assessment
  • Determining function and therapeutic value of novel gene targets
  • RNAi-based target validation: practical issues
  • Assessment and prioritisation of genes identified in genomics programs
  • 17:20 Chairman’s Closing Remarks and Close of Day One

    8:30 Re-registration and Coffee

    9:00 Chairman's Opening Remarks

    Dr Eugen Uhlmann

    Dr Eugen Uhlmann, Vice President, Chemical Development, Coley Pharmaceutical

    9:10 RESPIRABLE ANTISENSE OLIGONUCLEOTIDES

    Dr James Mannion

    Dr James Mannion, President & Chief Operating Officer, EpiGenesis Pharmaceuticals

  • Towards creating a blockbuster for common respiratory diseases
  • Clinical trial results: EPI-2010
  • RASONs as target validation tools
  • MT-RASONs: the next generation
  • 9:40 MOLECULAR BEACON TECHNOLOGY

    Dr Vinod Subramaniam

    Dr Vinod Subramaniam, Senior Research Scientist, Advanced Science & Technology Laboratory, AstraZeneca

  • Advantages of using molecular beacons
  • Triplex forming oligonucleotides (TFOs) as triplex DNA based therapeutic agents
  • using molecular beacons to monitor triplex DNA formation kinetics
  • Extracting thermodynamic and kinetic parameters
  • Future trends
  • 10:20 LOCKED NUCLEIC ACIDS (LNA) IN ANTISENSE

    Henrik Ørum

    Henrik Ørum, Chief Scientific Officer & Director, Business Development, Cureon

  • In vitro and in vivo antisense properties
  • Future perspectives
  • 11:00 Morning Coffee

    11:30 TARGETING CANCER BY REVERSING IMMUNOSUPPRESSION

    Dr Reimar Schlingensiepen

    Dr Reimar Schlingensiepen, Chief Operating Officer, Antisense Pharma

  • Mode of action
  • TGF-beta
  • Safety, tolerability, efficacy
  • Where do we go from here?
  • 12:00 ANTISENSE DELIVERY

    Chris Springate

    Chris Springate, President, ARC Pharmaceuticals

  • Antisense delivery issues
  • Systemic versus local delivery of antisense
  • Designing novel delivery strategies for oligonucleotides
  • Polymeric delivery systems for oligonucleotides
  • Oral delivery of antisense
  • Summary: Product development - challenges and opportunities
  • 12:00 Lunch

    13:40 CASE STUDY: AFFINITAC™

    Dr William John

    Dr William John, Senior Clinical Research Physician, Eli Lilly

  • Affinitac: an antisense drug to treat non-small cell lung cancer
  • A targeted antisense drug
  • Activity demonstrated in both chemotherapy naive and extensively treated patients
  • Indications for other cancers
  • Preparation for phase IV trials
  • 14:20 GENASENSE™ CLINICAL PROGRESS

    Dr Robert Klem

    Dr Robert Klem, Vice President & Chief Technical Officer, Genta

  • Mode of action of Genasense™
  • Specificity and potency
  • Low toxicity of Genasense™
  • Melanoma preclinical data
  • Clinical update of Genasense™ program
  • 15:00 CASE STUDY: AVI BIOPHARMA

    Dr Patrick Iversen

    Dr Patrick Iversen, Senior Vice President of Research & Development , AVI BioPharma
    View Bio

  • Neugene antisense technology
  • Mode of action
  • Clinical trials to date
  • Indications for cancer
  • Indications for cardiovascular restinosis
  • Preparation for FDA approval
  • 15:40 Afternoon Tea

    16:00 INTELLECTUAL PROPERTY

    David Harper

    David Harper, Partner, McDonnell, Boehnen, Hulbert & Berghoff

  • Patent issues in antisense
  • Recent political and legal developments
  • Developing an appropriate protection strategy
  • Reducing the risk of litigation
  • Defending your intellectual property
  • 16:40 MEETING THE OLIGONUCLEOTIDE MANUFACTURING CHALLENGE

    Dr Mark Douglas

    Dr Mark Douglas, Business Development Manager, Avecia Biotechnology

  • Manufacture of oligonucleotide API
  • Making materials for pre-clinical work through to post phase III
  • Management of the process
  • Future challenges to be faced
  • 17:20 Chairman's Closing Remarks and Close of Conference

    +

    Workshops

    SiRNA Design and Application
    Workshop

    SiRNA Design and Application

    The Hatton, at etc. venues
    14th February 2003
    London, United Kingdom

    The Hatton, at etc. venues

    51/53 Hatton Garden
    London EC1N 8HN
    United Kingdom

    The Hatton, at etc. venues

    HOTEL BOOKING FORM

    Title

    SubTitle
    speaker image

    Content


    Title


    Description

    Download


    WHAT IS CPD?

    CPD stands for Continuing Professional Development’. It is essentially a philosophy, which maintains that in order to be effective, learning should be organised and structured. The most common definition is:

    ‘A commitment to structured skills and knowledge enhancement for Personal or Professional competence’

    CPD is a common requirement of individual membership with professional bodies and Institutes. Increasingly, employers also expect their staff to undertake regular CPD activities.

    Undertaken over a period of time, CPD ensures that educational qualifications do not become obsolete, and allows for best practice and professional standards to be upheld.

    CPD can be undertaken through a variety of learning activities including instructor led training courses, seminars and conferences, e:learning modules or structured reading.

    CPD AND PROFESSIONAL INSTITUTES

    There are approximately 470 institutes in the UK across all industry sectors, with a collective membership of circa 4 million professionals, and they all expect their members to undertake CPD.

    For some institutes undertaking CPD is mandatory e.g. accountancy and law, and linked to a licence to practice, for others it’s obligatory. By ensuring that their members undertake CPD, the professional bodies seek to ensure that professional standards, legislative awareness and ethical practices are maintained.

    CPD Schemes often run over the period of a year and the institutes generally provide online tools for their members to record and reflect on their CPD activities.

    TYPICAL CPD SCHEMES AND RECORDING OF CPD (CPD points and hours)

    Professional bodies and Institutes CPD schemes are either structured as ‘Input’ or ‘Output’ based.

    ‘Input’ based schemes list a precise number of CPD hours that individuals must achieve within a given time period. These schemes can also use different ‘currencies’ such as points, merits, units or credits, where an individual must accumulate the number required. These currencies are usually based on time i.e. 1 CPD point = 1 hour of learning.

    ‘Output’ based schemes are learner centred. They require individuals to set learning goals that align to professional competencies, or personal development objectives. These schemes also list different ways to achieve the learning goals e.g. training courses, seminars or e:learning, which enables an individual to complete their CPD through their preferred mode of learning.

    The majority of Input and Output based schemes actively encourage individuals to seek appropriate CPD activities independently.

    As a formal provider of CPD certified activities, SMI Group can provide an indication of the learning benefit gained and the typical completion. However, it is ultimately the responsibility of the delegate to evaluate their learning, and record it correctly in line with their professional body’s or employers requirements.

    GLOBAL CPD

    Increasingly, international and emerging markets are ‘professionalising’ their workforces and looking to the UK to benchmark educational standards. The undertaking of CPD is now increasingly expected of any individual employed within today’s global marketplace.

    CPD Certificates

    We can provide a certificate for all our accredited events. To request a CPD certificate for a conference , workshop, master classes you have attended please email events@smi-online.co.uk

    Event Title

    Headline

    Text
    Read More

    I would like to speak at an event

    I would like to attend an event

    I would like to sponsor/exhibit at an event

    SIGN UP OR LOGIN

    Sign up
    Forgotten Password?

    Contact SMi GROUP LTD

    UK Office
    Opening Hours: 9.00 - 17.30 (local time)
    SMi Group Ltd, 1 Westminster Bridge Road, London, SE1 7XW, United Kingdom
    Tel: +44 (0) 20 7827 6000 Fax: +44 (0) 20 7827 6001
    Website: http://www.smi-online.co.uk Email: events@smi-online.co.uk
    Registered in England No: 3779287 VAT No: GB 976 2951 71




    Forgotten Password

    Please enter the email address you registered with. We will email you a new password.